J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

John­son & John­son’s ex­per­i­men­tal an­ti­body nipocal­imab re­duced the sever­i­ty of symp­toms re­lat­ed to two au­toim­mune con­di­tions — first in a piv­otal study for gen­er­al­ized myas­the­nia gravis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER